Co-expression of estrogen receptor and Apolipoprotein D in node positive operable breast cancer possible relevance for survival and effects of adjuvant tamoxifen in postmenopausal patients

Acta Oncologica

Volumn 48, Issue 4, 2009, Pages 514-521

  Søiland, Hvard ^a,c   Skaland, Ivar ^a,c   Varhaug, Jan Erik ^b,c   Kørner, Hartwig ^a,c   Janssen, Emiel A M ^a   Gudlaugsson, Einar ^a,c   Baak, Jan P A ^a,c,d   Søreide, Jon Arne ^a,c  

^a STAVANGER UNIVERSITY HOSPITAL   (Norway)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF BERGEN   (Norway)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN D; ESTROGEN RECEPTOR ALPHA; PLACEBO; PROGESTERONE RECEPTOR; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ADJUVANT CHEMOTHERAPY; AGE; ANALYSIS OF VARIANCE; BREAST TUMOR; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; DOWN REGULATION; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; RISK;

AGE FACTORS; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS, HORMONAL; APOLIPOPROTEINS D; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ESTROGEN RECEPTOR ALPHA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PROGNOSIS; TAMOXIFEN;

EID: 65549143633     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.1080/02841860802620613     Document Type: Article

References (24)

1. Yager JD, Davidson NE. Estrogen carcinogenesis in breast cancer. N Engl J Med 2006;/354:/270-82.
2. Bernardi D, Errante D, Galligioni E, Crivellari D, Bianco A, Salvagno L, et al. Treatment of breast cancer in older women. Acta Oncol Epub [cited September 26 2007] PubMed; PMID 17899452.
3. Pierga JY, Girre V, Laurence V, Asselain B, Dieras V, Jouve M, et al. Characteristics and outcome of 1755 operable breast cancers in women over 70 years of age. Breast 2004;/ 13:/369-75.
4. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: An overview of the randomised trials. Lancet 1998;351:1451-67.
5. Balbin M, Freije JM, Fueyo A, Sanchez LM, Lopez-Otin C. Apolipoprotein D is the major protein component in cyst fluid from women with human breast gross cystic disease. Biochem J 1990;/271:/803-7.
6. Søiland H, Søreide K, Janssen EA, Kørner H, Baak JP, Søreide JA. Emerging concepts of Apolipoprotein D with possible implications for breast cancer. Cell Oncol 2007;/29:/ 195-209.
7. Do Carmo S, Levros LC Jr, Rassart E. Modulation of Apolipoprotein D expression and translocation under specific stress conditions. Biochim Biophys Acta 2007;/1773:/ 954-69.
8. Simard J, Dauvois S, Haagensen DE, Levesque C, Merand Y, Labrie F. Regulation of progesterone-binding breast cyst protein GCDFP-24 secretion by estrogens and androgens in human breast cancer cells: A new marker of steroid action in breast cancer. Endocrinology 1990;/126:/3223-31.
9. Harding C, Osundeko O, Tetlow L, Faragher EB, Howell A, Bundred NJ. Hormonally-regulated proteins in breast secretions are markers of target organ sensitivity. Br J Cancer 2000;/82:/354-60.
10. Lea OA. Binding properties of progesterone-binding cyst protein, PBCP. Steroids 1988;/52:/337-8.
11. Søiland H, Janssen EAM, Kørner H, Varhaug JE, Skaland I, Gudlaugson E, et al. Apolipoprotein D predicts adverse outcome in patients over 70 years with operable breast cancer. Breast Cancer Res Treat Epub [cited March 11 2008]. PubMed; PMID 18330697.
12. Søreide JA, Lea OA, Anda O, Skarstein A, Varhaug JE, Kvinnsland S. Progesterone-binding cyst protein (PBCP) in operable breast cancer: Correlations with prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Anticancer Res 1991;/11:/601-5.
13. Gundersen S, Hannisdal E, Søreide JA, Skarstein A, Varhaug JE. Adjuvant tamoxifen for pre- and postmenopausal women with estrogen receptor positive, node positive breast cancer: A randomized study. Breast Cancer Res Treat 1995;/36:/49-53.
14. Tavassoli FA, Devilee P. Pathology and genetics of tumours of the breast and female genital organs. In: World Health Organization Classification of Tumours, Lyon: IARC Press; 2003. p 9-112.
15. Sobin LH, Wittekind C. Breast tumors. In: TNM classifications of malignant tumors. 6th ed. International Union Against Cancer (UICC). Hoboken, New Jersey: John Wiley & Sons; 2002. p 131-142.
16. Baak JP, van Diest PJ, Voorhorst FJ, van der Wall E, Beex LV, Vermorken JB, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005;/23:/5993-6001.
17. Søiland H, Skaland I, Janssen EA, Kørner H, Varhaug JE, Søreide JA, et al. Comparison of Apolipoprotein D determination methods in breast cancer. Anticancer Res 2008;/28:/ 673-80.
18. www.nbcg.no. Norwegian Breast Cancer Group (NBCG) [updated February 1 2008; cited May 6 2008]. Available from: http://www.nbcg.no/nbcg.blaaboka. html#Anchor-13-37516.
19. Diez-Itza I, Vizoso F, Merino AM, Sanchez LM, Tolivia J, Fernandez J, et al. Expression and prognostic significance of Apolipoprotein D in breast cancer. Am J Pathol 1994;/144:/ 310-20.
20. Do Carmo S, Seguin D, Milne R, Rassart E. Modulation of Apolipoprotein D and Apolipoprotein E mRNA expression by growth arrest and identification of key elements in the promoter. J Biol Chem 2002;/277:/5514-23.
21. Herynk MH, Parra I, Cui Y, Beyer A, Wu MF, Hilsenbeck SG, et al. Association between the estrogen receptor alpha A908G mutation and outcomes in invasive breast cancer. Clin Cancer Res 2007;/13:/3235-43.
22. Harrell JC, Dye WW, Harvell DM, Pinto M, Jedlicka P, Sartorius CA, et al. Estrogen insensitivity in a model of estrogen receptor positive breast cancer lymph node metastasis. Cancer Res 2007;/67:/10582-91.
23. Zilli M, Grassadonia A, Tinari N, Di Giacobbe A, Gildetti S, Giampirtro J, et al. Molecular mechanisms of endocrine resistance and their implication in the therapy of breast cancer. Biochim Biophys Acta 2008. E-pub: PMID:18804516.
24. Gjerde J, Kisanga ER, Hauglid M, Holm PI, Mellgren G, Lien EA. Identification and quantification of tamoxifen and four metabolites in serum by liquid chromatography-tandem mass spectrometry. J Chromatogr A 2005;/1082:/6-14.